UNSPSC 51285606: Lasalocid a

This classification denotes an antibiotic with the molecular formula C34H54O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W7V2ZZ2FWB, chemically known as 2,3-cresotic acid, 6-(7-(5-ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2h-pyra but more generally known as lasalocid, which bears US NIH Compound Identifier 3888. European Medicines Agency schedules Lasalocid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08406MIG.

UNSPSC 51285606 Lasalocid a is a Commodity code that does not align with actual state and local procurement activity in the recent solicitations tagged under it. The code nominally refers to a specific veterinary antibiotic, but the opportunities posted under this code cover naloxone (opioid reversal medication), safe drug deactivation systems, therapeutic pharmacy initiatives, medical and first aid supplies for fire rescue operations, and generic multi-source pharmaceuticals and over-the-counter products for state and local health systems. The mismatch between the code's name and the scope of work being solicited indicates either a cataloging error or an overly broad application of the code to cover multiple pharmaceutical and medical supply categories.

Recent activity under this code spans state health and human services commissions, county health departments, municipal fire departments, and cooperative purchasing alliances. Seminole County, Florida posted an IFB on June 30, 2026 (response due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission issued an RFI on April 3, 2026 regarding direct-to-manufacturer prescription programs; the City of Tampa's Purchasing Department posted an IFB on March 25, 2026 for medical and first aid supplies for the Tampa Fire Department with an estimated contract value of $700,000 and response due March 13, 2026, restricted to certified Small Local Business Enterprises with a 5 percent bid discount; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP due March 26, 2026 to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon. Geographic activity appears concentrated in Florida, Texas, Minnesota, and Oregon, with the cooperative purchasing vehicle showing multi-state participation. The code shows considerable fragmentation across health procurement categories and issuing bodies, suggesting either a taxonomy misalignment or use as a catch-all for pharmaceutical and medical supply procurement at state and local level.